Annual report pursuant to Section 13 and 15(d)

Summary of Significant Accounting Policies - Going concern (Details)

v3.19.3.a.u2
Summary of Significant Accounting Policies - Going concern (Details) - USD ($)
$ in Thousands
12 Months Ended
Feb. 07, 2020
Jan. 24, 2020
Jan. 13, 2020
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Cash and cash equivalents       $ 50,412 $ 68,379  
Marketable securities - available-for-sale debt securities       39,130 136,755  
Total stockholders' equity       123,638 246,885 $ 202,984
Net loss       (137,165) (95,514)  
Net cash used in operating activities       (112,507) (104,388)  
Revenue       $ 1,122 $ 59,505  
Subsequent events. | American Depository Shares (ADSs)            
Net proceeds $ 89,800          
Subsequent events. | American Depository Shares (ADSs) | Underwritten Public Offering            
Issuance of common stock (in shares)   21,000,000        
Subsequent events. | American Depository Shares (ADSs) | Over-Allotment Option            
Issuance of common stock (in shares) 3,150,000          
Subsequent events. | Astellas Pharma Inc.            
Upfront payment received     $ 50,000      
Research funding     $ 7,500